Beactica Contributes to Detailed Understanding of Innovative Cancer Drug
UPPSALA, Sweden, October 29, 2012 /PRNewswire/ –
Beactica, the Swedish drug discovery company with world-leading expertise in molecular
interactions, today announced its contribution to a key paper in the Journal of
Pharmacology and Experimental Therapeutics*. As part of a collaboration with Boehringer
Ingelheim, Beactica scientists provided important insights into the interactions between
afatinib (BIBW 2992) and members of the ErbB receptor family. The results presented in the
paper provide a mechanistic rationale for the distinct pharmacological features of the
compound and explain the clinical activity seen in some patients resistant to antibody or
kinase inhibitor therapy.
“There is a growing awareness in the pharmaceutical industry about the importance of
interaction mechanism and kinetics for drug efficacy,” said Beactica’s CEO, Dr Per
Kallblad. “The results show that our scientific team is at the very forefront of this
Beactica has established relationships with five of the global top-20 pharmaceutical
companies as well as a growing number of biotech companies. The collaboration with
Boehringer Ingelheim is ongoing since 2008.
* Publication reference
Solca et al., Target binding properties and cellular activity of Afatinib (BIBW 2992),
an irreversible ErbB family blocker, Journal of Pharmacologyand Experimental Therapeutics,
2012, 343:342-350. (DOI: 10.1124/jpet.112.197756).
Beactica AB is a specialist drug discovery company, utilising its proprietary
methodologies to evaluate the interactions of molecules in order to generate novel and
mechanistically defined therapeutics. The Company offers expertise and services in the
area of SPR biosensor-based small molecule interaction analysis and partnerships for
fragment-based lead generation using its proprietary Sprint(TM) platform. Founded in 2006
based on research carried out at Uppsala University and first-hand experience from the
drug discovery industry, Beactica has established a robust reputation as the leader in
SPR-based small molecule drug discovery. As well as providing services and building
collaborations with external companies, Beactica is progressing its own drug discovery
programmes. For more information, please visit http://www.beactica.com.
For additional information please contact Dr Per Kallblad, Beactica CEO,
SOURCE Beactica AB